Start here if you're new
what it is
Fate Therapeutics is trying to mass-produce immune cells to fight cancer and autoimmune disease without custom-building each dose.
how it gets paid
Last year Fate Therapeutics made $7M in revenue. collaboration revenue was the main engine at $3.0M, or 43% of sales.
why growth slowed
Revenue fell 51.2% last year. $5M of quarterly revenue sounds better until you stack it against a n/a operating margin.
what just happened
Latest reported quarter revenue hit $5M, but the real story is that losses still overwhelmed a business this small.
At a glance
C+ balance sheet — struggling to keep the lights on
65/100 earnings predictability — reasonably predictable
-$1.64 fy2024 eps est
$14M fy2024 rev est
n/a operating margin
xvary composite: 31/100 — weak
What they do
Fate Therapeutics is trying to mass-produce immune cells to fight cancer and autoimmune disease without custom-building each dose.
The pitch is simple: make cell therapy off-the-shelf instead of one-patient-at-a-time. iPSC platform (induced pluripotent stem cells → starter cells that can become immune fighters → so what: you can manufacture at scale) is the whole bet, and Fate already runs its own GMP facility with 181 employees. If this works, you get repeatable supply; if it fails, you own a company with $7 million of annual revenue and losses everywhere.
How they make money
$7M
annual revenue · their business grew -51.2% last year
collaboration revenue
$3.0M
flat
license revenue
$1.8M
dn
research services
$1.2M
up
manufacturing support
$0.6M
up
milestone-related revenue
$0.4M
dn
The products that matter
iPSC-derived CAR T-cell therapy
FT819
16 sites
This lead candidate is already being studied in lupus across 16 sites. For a company with a $136M market cap, this is the program most likely to move the stock.
lead program
cell therapy manufacturing platform
iPSC Platform
$205M cash backing
The platform is the entire thesis. It is funded by $205M of cash today, but it still has zero approved products and has to justify the spend before runway runs out.
platform bet
early-stage autoimmune and oncology pipeline
Preclinical Pipeline
$136M market cap
You are getting the rest of the pipeline for less than cash because the stock trades at a $136M market cap versus $205M in cash. That sounds cheap until you remember early-stage programs can stay early-stage for a long time.
option value
Key numbers
$14M
2024 revenue est.
That is the 2024 sales estimate from the base data. Plain English: this is still a tiny business, so the stock trades on pipeline hope, not current sales.
n/a
operating margin
Prior margin KPI failed sanity check — verify in filings. Operating margin → profit after running the business → so what: Fate loses more than $22 for every $1 it brings in.
$74M
long-term debt
Debt is 35% of capital. Plain English: a company with $7M of annual revenue is carrying a real balance-sheet burden.
1.8
beta
Beta → how violently the stock moves versus the market → so what: these shares have historically swung about 80% more than the broader market.
Financial health
C+
strength
- balance sheet grade C+ — weak — may struggle to fund operations
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $74M (35% of capital)
C+ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for FATE right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Latest reported quarter revenue hit $5M, but the real story is that losses still overwhelmed a business this small.
SEC-verified data showed quarterly revenue of $5M, up 203% vs. prior year, with EPS of -$0.88. Contrast matters: $5M of sales versus a projected full-year EPS loss of -$1.64 is not operating leverage. It is a reminder that clinical biotechs can grow revenue and still burn cash.
$5M
revenue
$0.88
eps
+203%
revenue growth
the number that mattered
$5M of quarterly revenue sounds better until you stack it against a n/a operating margin. Sales exist, but the business model still does not.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the top risk here is FT819 failing to produce convincing autoimmune data before the cash runway gets uncomfortably short.
med
FT819 data disappoints
All the upside points back to one thing: proving the off-the-shelf cell therapy concept in autoimmune disease. The stock is cheap because the market does not trust that yet.
If FT819 fails to show meaningful efficacy or tolerability, you are left with a company that has cash but no credible engine for re-rating.
med
runway shrinks faster than expected
Management says $205.1M of cash and investments supports operations into 2027. That is useful, not generous, for a company losing money at this scale.
If burn stays elevated and there is no clear data win, dilution becomes the obvious next chapter.
med
manufacturing complexity never becomes an advantage
The platform thesis assumes iPSC-derived cell therapies can be made faster and more broadly than patient-specific approaches. That is a scientific and operational claim, not a proven business model.
If the manufacturing story stays more interesting than commercial, the market keeps valuing Fate below cash and treats the platform like an expensive experiment.
med
ownership concentration amplifies every move
About 97.5% of shares are held by institutions. In small-cap biotech, that can mean sharp price swings when one fund changes its mind.
You are not just underwriting science. You are also underwriting the behavior of a concentrated holder base in a thinly valued stock.
The combined risk picture is simple: $205M of cash covers about 151% of the $136M market cap, but that only matters if the company reaches a real clinical inflection before runway pressure turns cheap into diluted.
source: institutional data · regulatory filings · risk analysis
Pay attention to
catalyst
FT819 lupus data
This is the next real credibility check. Management has pointed to data in 2026, even if the exact date is not pinned down here.
metric
cash balance versus market cap
Today the company has $205M of cash against a $136M market cap. If that gap narrows without clinical progress, the margin of safety gets thinner fast.
risk
runway guidance into 2027
Every quarter should answer the same question: is the runway still into 2027, or is the cash clock moving faster than expected.
trend
autoimmune replacing oncology as the story
The strategic pivot matters. A broader autoimmune market is the bull case, but you need proof that the platform travels well outside its earlier oncology framing.
Analyst rankings
earnings predictability
65 / 100
This is better than you might expect for a biotech because the loss profile is fairly steady. In human-speak, analysts think the company will keep losing money in a relatively unsurprising way.
beta
1.8
Beta measures market sensitivity. At 1.8, the stock has tended to move much more than the market. You should expect exaggerated swings when sentiment shifts.
source: institutional data
Institutional activity
institutional ownership data for FATE is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$1
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive